or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, ...

Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): Phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept ...

agonist that was first approved in 2020 for patients six years and older with obesity due to rare genetic diseases proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1 ...

proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency and leptin receptor (LEPR) deficiency in 2020; and for people with Bardet-Biedl syndrome in 2022. New top-line data from the phase ...

They compared the functional coding variants of these individuals with those of their families and controls and discovered two extremely rare functional IGF-1 mutations (propeptide numbering ...

proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency or leptin receptor (LEPR) deficiency in 2020. The FDA’s original approvals for setmelanotide were for children and adults aged 6 ...

If you need medicine to lower your cholesterol, chances are your doctor will prescribe a statin. But these drugs aren’t always enough. And some people can’t take them because of their side ...

LYON, France — Lerodalcibep, a novel, third-generation anti–proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, helps high-risk patients already receiving maximally tolerated ...

Repatha, a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor, is indicated as adjunctive therapy to reduce low-density lipoprotein cholesterol (LDL-C): in adults with primary ...

Accordingly, doctors often prescribe lipid-lowering medications (e.g. statins and proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors) for treating CVDs. These "block-buster" drugs ...

A strong warning has been issued for evolocumab (Repatha) by researchers from Spain and Canada on use of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor among adult patients ...

Consequently, it is secreted into the lumen, where an inhibitory propeptide is removed to produce active PSA. It subsequently undergoes proteolysis to produce an inactive form of PSA; from here ...